Want to see JP:4883 full AI Analyst Report?
Top Page
Modalis Therapeutics Corporation
(4883)
Select Model
Select Model
Rating:41Neutral
Price Target:
¥32.00
▼(-42.86% Downside)
Action:Reiterated
Date:06/26/26
The score is primarily weighed down by weak financial performance (minimal revenue, large recurring losses, and sustained cash burn) and bearish technical trends (price below key moving averages with negative MACD). Valuation provides little offset because earnings are negative (negative P/E) and no dividend yield is available.
Positive Factors
Proprietary epigenetic medicine platform
A proprietary gene-regulation platform could support multiple therapeutic programs and create licensing or partnership opportunities. Its value is tied to reusable discovery capabilities rather than a single asset, although clinical validation remains necessary.
Negative Factors
Minimal or absent revenue
The lack of reported revenue indicates that the business has not yet established a commercial product or dependable operating income stream. This leaves future value heavily dependent on clinical progress, partnerships, licensing, or external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary epigenetic medicine platform
A proprietary gene-regulation platform could support multiple therapeutic programs and create licensing or partnership opportunities. Its value is tied to reusable discovery capabilities rather than a single asset, although clinical validation remains necessary.
Read all positive factors
Modalis Therapeutics Corporation (4883) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥3.44B
Dividend YieldN/A
Average Volume (3M)719.68K
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue GrowthN/A
EPS Growth-5.66%
CountryJP
Employees17
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-22.80
Shares Outstanding104,374,100
10 Day Avg. Volume617,120
30 Day Avg. Volume719,680
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)1.55
Price to Sales (P/S)0.00
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.2
Revenue Forecast (FY)¥800.00M
Modalis Therapeutics Corporation Business Overview & Revenue Model
Company Description
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic ...
How the Company Makes Money
Modalis Therapeutics primarily seeks to generate revenue through the development and monetization of its drug discovery platform and pipeline. Potential revenue streams for a clinical-stage biotech of this type typically include (i) upfront paymen...
Modalis Therapeutics Corporation Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
54
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 40.50M | 1.10M |
| Gross Profit | -583.00K | 0.00 | 0.00 | -731.00K | -83.17M | 1.10M |
| EBITDA | -1.88B | -2.21B | -2.15B | -2.37B | -2.58B | -667.55M |
| Net Income | -1.82B | -2.15B | -1.32B | -2.39B | -2.70B | -738.96M |
Balance Sheet | ||||||
| Total Assets | 2.94B | 2.96B | 3.69B | 2.03B | 3.13B | 6.07B |
| Cash, Cash Equivalents and Short-Term Investments | 2.81B | 2.81B | 3.58B | 1.88B | 2.93B | 4.94B |
| Total Debt | 0.00 | 0.00 | 0.00 | 412.50M | 0.00 | 0.00 |
| Total Liabilities | 142.55M | 170.94M | 143.47M | 645.50M | 188.60M | 519.92M |
| Stockholders Equity | 2.80B | 2.79B | 3.55B | 1.38B | 2.94B | 5.55B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -2.12B | -1.43B | -2.29B | -2.09B | -854.58M |
| Operating Cash Flow | 0.00 | -2.12B | -1.43B | -2.25B | -1.90B | -747.47M |
| Investing Cash Flow | 0.00 | -2.57M | -188.00K | -39.70M | -185.72M | 171.56M |
| Financing Cash Flow | 0.00 | 1.35B | 3.04B | 1.22B | 63.68M | 72.63M |
Modalis Therapeutics Corporation Technical Analysis
Neutral
56.00
Price Trends
32.62
Positive
43.01
Negative
51.98
Negative
Market Momentum
-0.08
Negative
50.84
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4883, the sentiment is Neutral. The current price of 56 is above the 20-day moving average (MA) of 32.25, above the 50-day MA of 32.62, and above the 200-day MA of 51.98, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 50.84 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4883.
Modalis Therapeutics Corporation Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | ¥13.42B | 19.28 | ― | ― | 13.30% | 66.38% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ¥5.68B | -45.84 | ― | 3.21% | 0.60% | -131.22% | |
50 Neutral | ¥7.92B | -9.01 | -54.56% | ― | 32.42% | 61.00% | |
44 Neutral | ¥4.97B | -0.63 | ― | ― | -37.69% | 1.85% | |
44 Neutral | ¥5.75B | -7.00 | ― | ― | 364.72% | 18.43% | |
41 Neutral | ¥3.44B | -1.37 | ― | ― | ― | -5.66% |
* General Sector Average
JP:4883
Modalis Therapeutics Corporation
33.00
-54.00
-62.07%
JP:4597
Solasia Pharma KK
30.00
-7.00
-18.92%
JP:4539
Nippon Chemiphar Co., Ltd.
1,574.00
3.84
0.24%
JP:4574
Taiko Pharmaceutical Co., Ltd.
264.00
-41.00
-13.44%
JP:4582
Symbio Pharmaceuticals Limited
63.00
-85.00
-57.43%
JP:4892
Cyfuse Biomedical K.K.
570.00
-52.00
-8.36%
Modalis Therapeutics Corporation Corporate Events
Modalis Therapeutics Issues Further Corrections to Interim Financial Results
Aug 14, 2026
Modalis Therapeutics Corporation announced further corrections to its consolidated financial results for the six months ended June 30, 2026, under Japanese GAAP. The adjustments affect explanatory materials linked to second-quarter balance sheet, ...
Modalis Revises Interim Results After R&D Expense Timing Error
Aug 14, 2026
Modalis Therapeutics Corporation reported consolidated financial results for the six months ended June 30, 2026, under Japanese GAAP, showing continued operating losses, negative ordinary income, and a basic loss per share, but maintaining a solid...
Modalis Corrects Presentation Errors in Mid-Year Financial Report Without Impacting Results
Aug 10, 2026
Modalis Therapeutics Corporation announced corrections to its Business and Financial report for the six months ended June 30, 2026, noting that certain descriptive elements in its financial presentation materials contained errors. The company clar...
Modalis Books FX Gains and R&D Refund as One-Off Income Boost
Aug 10, 2026
Modalis Therapeutics Corporation reported non-operating income and extraordinary income for the six months ended June 30, 2026, highlighting specific one-off financial gains. The company recorded 6 million yen in foreign exchange income as non-ope...
Modalis Issues English Reference Version of Q2 2026 Financial Report
Aug 10, 2026
Modalis Therapeutics released an English reference translation of its second-quarter 2026 business and financial report, dated August 10, 2026. The document is designated as a translation of the original Japanese report, with the company stating t...
Modalis Therapeutics Narrows Interim Loss but Withholds 2026 Outlook
Aug 10, 2026
Modalis Therapeutics reported an interim consolidated loss for the six months ended June 30, 2026, with operating income at minus ¥1,000 million and profit attributable to owners of the parent at minus ¥920 million, narrowing slightly fr...
Modalis Highlights CRISPR-GNDM Platform as Cornerstone of Rare Disease Growth Strategy
Jul 14, 2026
Modalis Therapeutics has outlined its growth-oriented business plans centered on its CRISPR-GNDM technology platform for rare diseases. The company highlights key attributes of this approach, including long-lasting therapeutic effects over years o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.